Galapagos Begins Phase 2b/3 Clinical Trial of Filgotinib in Ulcerative Colitis Patients

Galapagos Begins Phase 2b/3 Clinical Trial of Filgotinib in Ulcerative Colitis Patients
Galapagos NV recently announced that it has dosed the first patient with ulcerative colitis (UC) in its SELECTION Phase 2b/3 clinical trial, investigating the efficacy and safety of two doses of filgotinib as a UC treatment. SELECTION  (NCT02914522) is investigating two doses of filgotinib (100 mg and 200 mg filgotinib once daily), compared to placebo, as an induction and maintenance treatment for people with moderately to severely active ulcerative colitis. The trial is currently recruiting participants, including those who have failed to respond to previous treatments with biologics. In total, about 1,300
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *